Literature DB >> 31627804

Similarities and differences between Likert and PIRADS v2.1 scores of prostate multiparametric MRI: a pictorial review of histology-validated cases.

A Latifoltojar1, M B Appayya1, T Barrett2, S Punwani3.   

Abstract

The UK National Institute for Health and Care Excellence (NICE) 2019 "Prostate cancer: diagnosis and management" guidelines have recommended that all patients suspected of prostate cancer undergo multiparametric magnetic resonance imaging (mpMRI) prior to biopsy. The Likert scoring system is advocated for mpMRI reporting based on multicentre studies that have demonstrated its effectiveness within the National Health Service (NHS). In recent years, there has been considerable drive towards standardised prostate reporting, which led to the development of "Prostate Imaging-Reporting And Data System" (PI-RADS). The PI-RADS system has been adopted by the majority of European countries and within the US. This paper reviews these systems indicating the similarities and specific differences that exist between PI-RADS and Likert assessment through a series of histologically proven clinical cases.
Copyright © 2019. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31627804     DOI: 10.1016/j.crad.2019.08.020

Source DB:  PubMed          Journal:  Clin Radiol        ISSN: 0009-9260            Impact factor:   2.350


  6 in total

1.  Comparison of Likert and PI-RADS version 2 MRI scoring systems for the detection of clinically significant prostate cancer.

Authors:  Jeries P Zawaideh; Evis Sala; Maria Pantelidou; Nadeem Shaida; Brendan Koo; Iztok Caglic; Anne Y Warren; Luca Carmisciano; Kasra Saeb-Parsy; Vincent J Gnanapragasam; Christof Kastner; Tristan Barrett
Journal:  Br J Radiol       Date:  2020-06-11       Impact factor: 3.039

2.  Evaluation of PSA and PSA Density in a Multiparametric Magnetic Resonance Imaging-Directed Diagnostic Pathway for Suspected Prostate Cancer: The INNOVATE Trial.

Authors:  Hayley Pye; Saurabh Singh; Joseph M Norris; Lina M Carmona Echeverria; Vasilis Stavrinides; Alistair Grey; Eoin Dinneen; Elly Pilavachi; Joey Clemente; Susan Heavey; Urszula Stopka-Farooqui; Benjamin S Simpson; Elisenda Bonet-Carne; Dominic Patel; Peter Barker; Keith Burling; Nicola Stevens; Tony Ng; Eleftheria Panagiotaki; David Hawkes; Daniel C Alexander; Manuel Rodriguez-Justo; Aiman Haider; Alex Freeman; Alex Kirkham; David Atkinson; Clare Allen; Greg Shaw; Teresita Beeston; Mrishta Brizmohun Appayya; Arash Latifoltojar; Edward W Johnston; Mark Emberton; Caroline M Moore; Hashim U Ahmed; Shonit Punwani; Hayley C Whitaker
Journal:  Cancers (Basel)       Date:  2021-04-20       Impact factor: 6.575

3.  Diagnostic Accuracy of Abbreviated Bi-Parametric MRI (a-bpMRI) for Prostate Cancer Detection and Screening: A Multi-Reader Study.

Authors:  Giorgio Brembilla; Francesco Giganti; Harbir Sidhu; Massimo Imbriaco; Sue Mallett; Armando Stabile; Alex Freeman; Hashim U Ahmed; Caroline Moore; Mark Emberton; Shonit Punwani
Journal:  Diagnostics (Basel)       Date:  2022-01-18

4.  Comparison of different thresholds of PSA density for risk stratification of PI-RADSv2.1 categories on prostate MRI.

Authors:  Rossano Girometti; Gianluca Giannarini; Valeria Panebianco; Silvio Maresca; Lorenzo Cereser; Maria De Martino; Stefano Pizzolitto; Martina Pecoraro; Vincenzo Ficarra; Chiara Zuiani; Claudio Valotto
Journal:  Br J Radiol       Date:  2021-11-11       Impact factor: 3.039

Review 5.  Current Opinion on the Use of Magnetic Resonance Imaging in Staging Prostate Cancer: A Narrative Review.

Authors:  Jamie Michael; Kevin Neuzil; Ersan Altun; Marc A Bjurlin
Journal:  Cancer Manag Res       Date:  2022-03-01       Impact factor: 3.989

Review 6.  Diagnostic Performance of a Magnetic Resonance Imaging-directed Targeted plus Regional Biopsy Approach in Prostate Cancer Diagnosis: A Systematic Review and Meta-analysis.

Authors:  Marinus J Hagens; Mar Fernandez Salamanca; Anwar R Padhani; Pim J van Leeuwen; Henk G van der Poel; Ivo G Schoots
Journal:  Eur Urol Open Sci       Date:  2022-05-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.